GSK is ending its neuroscience collaboration with Alector after two experimental antibody drugs — latozinemab and nivisnebart — both failed in clinical trials. Latozinemab flopped in a late-stage study for a rare inherited form of frontotemporal dementia, while nivisnebart's mid-stage Alzheimer's trial was discontinued after an interim analysis showed it was unlikely to hit its primary goal. The termination takes effect January 2, 2027.
GSK is officially walking away from its neuroscience partnership with Alector after both experimental antibody drugs at the center of their collaboration came up short in clinical trials. The termination of their 2021 collaboration and license agreement — which covered monoclonal antibodies latozinemab and nivisnebart — will take effect on January 2, 2027, following a 180-day notice period that began July 6.
The setbacks were significant: latozinemab failed a late-stage study in a rare inherited form of frontotemporal dementia, and nivisnebart's mid-stage Alzheimer's disease trial was discontinued in April after an interim analysis suggested it was unlikely to meet its primary endpoint. The fallout for Alector was severe — the company cut nearly half its workforce following latozinemab's failure.
By the Numbers:
Why it matters: This dissolution underscores the continued difficulty of developing effective treatments for Alzheimer's disease and frontotemporal dementia — two conditions with enormous unmet need and a long history of clinical trial failures.
